"Peptidyl-Dipeptidase A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, -Xaa-*-Xbb-Xcc, when neither Xaa nor Xbb is Pro. It is a Cl(-)-dependent, zinc glycoprotein that is generally membrane-bound and active at neutral pH. It may also have endopeptidase activity on some substrates. (From Enzyme Nomenclature, 1992)
| Descriptor ID |
D007703
|
| MeSH Number(s) |
D08.811.277.656.350.350.687
|
| Concept/Terms |
Peptidyl-Dipeptidase A- Peptidyl-Dipeptidase A
- Peptidyl Dipeptidase A
- Angiotensin I-Converting Enzyme
- Angiotensin I Converting Enzyme
- Carboxycathepsin
- CD143 Antigens
- Kininase II
- Dipeptidyl Peptidase A
- Antigens, CD143
- Angiotensin Converting Enzyme
- Kininase A
|
Below are MeSH descriptors whose meaning is more general than "Peptidyl-Dipeptidase A".
Below are MeSH descriptors whose meaning is more specific than "Peptidyl-Dipeptidase A".
This graph shows the total number of publications written about "Peptidyl-Dipeptidase A" by people in this website by year, and whether "Peptidyl-Dipeptidase A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2003 | 0 | 3 | 3 |
| 2004 | 4 | 6 | 10 |
| 2005 | 1 | 14 | 15 |
| 2006 | 11 | 3 | 14 |
| 2007 | 5 | 2 | 7 |
| 2008 | 7 | 2 | 9 |
| 2009 | 7 | 1 | 8 |
| 2010 | 4 | 0 | 4 |
| 2011 | 1 | 3 | 4 |
| 2012 | 3 | 3 | 6 |
| 2013 | 3 | 3 | 6 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 7 | 6 | 13 |
| 2018 | 16 | 2 | 18 |
| 2019 | 2 | 1 | 3 |
| 2020 | 156 | 224 | 380 |
| 2021 | 14 | 32 | 46 |
To return to the timeline, click here.
Below are the most recent publications written about "Peptidyl-Dipeptidase A" by people in Profiles.
-
Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19-related Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2021 11 01; 204(9):1024-1034.
-
In-hospital use of ACE inhibitors/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients. J Clin Invest. 2021 10 01; 131(19).
-
Viral stimulation modulates endotype-related ACE2 expression in eosinophilic chronic rhinosinusitis. Rhinology. 2021 Oct 01; 59(5):460-469.
-
Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS One. 2021; 16(9):e0257016.
-
COVID-19: a fatal case of acute liver failure associated with SARS-CoV-2 infection in pre-existing liver cirrhosis. BMC Infect Dis. 2021 Sep 03; 21(1):901.
-
Angiotensin-converting enzyme 2 decreased expression during kidney inflammatory diseases: implications to predisposing to COVID-19 kidney complications. Kidney Int. 2021 11; 100(5):1138-1140.
-
Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity. J Chem Inf Model. 2021 09 27; 61(9):4656-4669.
-
Key Interacting Residues between RBD of SARS-CoV-2 and ACE2 Receptor: Combination of Molecular Dynamics Simulation and Density Functional Calculation. J Chem Inf Model. 2021 09 27; 61(9):4425-4441.
-
Antiviral response in vernal keratoconjunctivitis may be protective against COVID-19. Allergy. 2022 01; 77(1):298-300.
-
The Angiotensin Converting Enzyme Deletion/Deletion Genotype Is a Risk Factor for Severe COVID-19: Implication and Utility for Patients Admitted to Emergency Department. Medicina (Kaunas). 2021 Aug 20; 57(8).